sangamo investor relations

Pioneering Genetic Cures. new Date().getFullYear()>2010&&document.write(new Date().getFullYear()); Sangamo Therapeutics is committed to translating ground-breaking science into genomic … new Date().getFullYear()>2010&&document.write(new Date().getFullYear()); Source: Pfizer Inc. View all Press Releases. Pfizer Investor Relations: Bryan Dunn 212.733.8917 [email protected] Sangamo Investor & Media Relations Aron Feingold 628.252.7494 [email protected] Source: Pfizer Inc. Show. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. Sangamo Investor & Media Relations Aron Feingold 628.252.7494 afeingold@sangamo.com. Corporate Profile. The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. History. Quarterly Reports; Annual Reports; SEC Filings; Interactive Data Filings ; Viatris Transaction; Investor … Mr. Lee’s last day of employment will be February 1, 2021 . Sangamo . Sangamo Therapeutics is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation.The optionality and diversity inherent to Sangamo… ]]> Pioneering Genetic Cures. Healthy Living. Message board - Online Community of active, educated investors researching and discussing Sangamo Therapeutics, Inc. Stocks. Originally published December 7, 2020, 7:00 AM. ]]> Upon closing of this transaction, Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share. Product Pipeline. Investor Contacts. Footer menu. INVESTOR CONTACTS: Biogen Idec Carlo Tanzi, Ph.D. Director, Investor Relations Ph: (781) 464-2442 IR@biogenidec.com. Sangamo Therapeutics is committed to translating ground-breaking science into genomic … Sangamo Therapeutics, Inc. About Sangamo Therapeutics . Prospective Investors; Sustainability Bond; Fact Sheet; Events & Presentations; Financials. Message board - Online Community of active, educated investors researching and discussing Sangamo Therapeutics, Inc. Stocks. D. Mark McClung has served as Sangamo’s Executive Vice President and Chief Business Officer since May 2020. Inventiva 50 rue de Dijon 21121 Daix, France Email: finance@inventivapharma.com Tel: +33 (0)3 80 44 75 00. //-->